Gilberto Lopes, MD, MBA, on NSCLC: Results From the KEYNOTE-042 Trial
2018 ASCO Annual MeetingGilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, discusses phase III findings on pembrolizumab vs platinum-based chemotherapy as first-line treatment for advanced/metastatic non–small cell lung cancer with a PD-L1 tumor proportion score ≥ to 1% (Abstract LBA4).
Related Videos
Tony Mok, MD, on NSCLC: Results From the ARCHER 1050 Trial
Tony Mok, MD, of the Chinese University of Hong Kong, discusses study findings on dacomitinib vs gefitinib for first-line treatment of advanced non–small cell lung cancer, a final ...
Bruce E. Johnson, MD, and Monica M. Bertagnolli, MD, on The ASCO Presidency: Passing the Torch
Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology and ASCO’s outgoing President, talks with Monica M. Bertagnolli, MD, of Brigham and Women’s Hospital...
Raymond U. Osarogiagbon, MBBS, on NSCLC: A Lymph Node Collection Kit
Raymond U. Osarogiagbon, MBBS, of Baptist Cancer Center, discusses a kit used in non–small cell lung cancer resection that improves staging quality and overall survival without add...
Sherry Shen, MD, on Breast Cancer and Obesity: Results of the SWOG S0927 Study
Sherry Shen, MD, of Columbia University Medical Center, discusses findings on the use of omega-3 fatty acid for obese breast cancer patients with aromatase inhibitor–related arthra...
Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial
Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early b...
